likely to be collaborating with a commercial partner, and where they did, it was often with an American company. Important questions about the future development of gene therapy remain unanswered. What are the main In contrast, most leading researchers in the USA were working closely with domestic gene therapy firms. An barriers to the process of converting today's science into tomorrow's technology? How might these obstacles be important reason for this was the relative strength of the gene therapy industries. American gene therapy firms overcome? Which countries are best placed to reap the rewards promised by gene therapy? These matters are employ three times as many staff, are sponsoring five times as many clinical trials and are much better financed not traditionally raised in a scientific journal as they concern the worlds of commerce and public policy, yet they than the 12 dedicated firms in Europe. So although European investigators are keen to work with industry, they must be addressed by the scientific community if basic research is going to be successfully translated into new have fewer opportunities to do so. The result is that the European science base is less exploited than in the USA treatments.
In a major study for the European Commission, 1 we and a significant number of the benefits of public research are being exported abroad. have tried to examine these issues by undertaking a broad survey of the development of gene therapy in EurAnother consequence of the commercialisation gap is that the pharmaceutical industry is making almost all its ope and the USA, and a detailed comparative analysis of the innovation process in the UK and the USA. The main external investment in this area in North America. Since 1993, there has been a trend towards the integration of finding of the research was that Europe lags some 3 to 5 years behind the USA in terms of both the clinical and gene therapy into the pharmaceutical sector, with large companies investing heavily in acquisitions and alliances commercial development of the technology. European clinical trials are generally at an earlier stage and firms with small gene therapy firms. The lack of these firms in Europe is a major reason why large companies created are further from launching commercial products than their American rivals.
29 commercial collaborations related to gene therapy in the USA between 1992 and 1996, compared with only One factor explaining this is the sheer scale of the gene therapy research effort in the USA, which produces twice three in Europe. However, the pattern of financing presents a paradox, as European pharmaceutical compaas many scientific publications and supports three times as many clinical trials as the whole of Europe. Interestnies have invested $1.4 billion in the American gene and cell therapy industries during this period, compared with ingly, the overall pattern of clinical trials is the same and there are no major differences in the regulation of clinical just $140 million by their American counterparts. So although small American firms are leading the world in research, with several European countries simply amending the RAC guidelines. In the area of clinical developdeveloping the technology and are actively exploiting the European science base, it is the European pharmaceutical ment the study identified a number of common barriers to translational research in both the USA and Europe.
industry which may ultimately benefit most from the successful development of gene therapy in the USA. These included difficulties in getting access to research materials owned by firms and problems with the If Europe is to profit most from its publicly funded research, creating local jobs and building an interproduction of vectors for clinical trials sponsored by academics.
nationally competitive gene therapy industry, then it must overcome the barriers to the commercialisation of However, the main difference between EU states and the USA appears to lie in the way in which gene therapy its science base. There are three key areas which the research community and public policy makers need to is being developed by industry. This has created a 'commercialisation gap' in Europe, with basic research less address. First, there has to be a 'critical mass' of basic research in order to support a strong gene therapy indusintensively exploited, and fewer dedicated gene therapy firms created, than in the USA. This is a key issue, as it try. The size and concentration of US research is illustrated by the fact that the top five research centres workis essential to have an effective process of innovation linking academic research and industry. Only firms have ing on gene therapy in the USA are directly comparable to the top five European countries, as measured by publithe resources and expertise in production, regulatory affairs and clinical development, to translate gene thercations output and the number of clinical trials undertaken. Research from these five US institutes alone has apy into new products for use in hospitals and clinics.
This European gap between academia and industry helped established over 10 American gene therapy firms.
Coherent policies should therefore be established compete internationally. The adoption of Orphan Drug legislation in the EU would greatly help in this respect. throughout Europe, such as those in Germany and
Research in the whole field of human genetics is France, to promote gene therapy as a national priority, unusual in being so closely tied to industrial innovation, with the emphasis on creating large centres of excellence. and it is the USA which is leading the world in turning Second, the formal process of technology transfer has to good science into promising technology. 2 If gene therapy be improved. Although significant progress has been is to realise its potential as a new therapeutic modality, made in this area in recent years, the sophisticated techthen it is vital that Europe makes its full contribution in nology transfer programmes found in many US univerthis area by overcoming the barriers to successful innosities and research institutes are far less common in vation and building stronger bridges between academia Europe. Governments need to give greater priority to this and industry. area and significantly increase investment in technology transfer initiatives. In addition, European academics PA Martin should be given greater opportunities and incentives to Science Policy Research Unit exploit their research commercially.
Mantell Building Finally, the most important area for concerted action University of Sussex by government and industry is to assist the creation and Falmer development of new gene therapy firms. It is widely Brighton BN1 9RF, UK accepted that it is more difficult to start a new biotechnology company in Europe compared with the USA,
